Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nuance Pharma Closes $181 Million D Round for In-licensed Drugs

publication date: Dec 8, 2020

Shanghai's Nuance Pharma closed a $181 million Series D financing to develop drugs for iron deficiency, pain management and respiratory conditions. The company will use the proceeds to develop its existing pipeline and acquire new assets. Founded in 2014, Nuance has been supported by VCs that include CBC Group (formerly C-Bridge Capital) and Matrix Partners China. At the time of the B round, CBC said its $35 million investment was a "unique funding model" that allowed the venture firm to build a China pharma. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital